



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 06 Feb 2018 (#3)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices

- [A Refresher on Subawards](#) Learn your requirements and responsibilities if you want to use a subaward to augment your own expertise and improve the efficiency of your research.
- [Revised Clinical Trial Case Studies and Updated FAQs](#) To help researchers determine whether their proposed study is a clinical trial (CT), NIH revised its existing case studies and posted a few new ones to clarify how the CT definition does or doesn't apply to certain types of studies.
- [NIH Announces Inclusion Across the Lifespan Policy](#) NIH announced a revision ([NOT-OD-18-116](#)) to a decades-old policy originally conceived in response to concerns that children were not appropriately included in clinical research. These changes broaden the policy to address inclusion of research participants of all ages, and as discussed at the last Advisory Committee to the NIH Director meeting, will apply beginning in 2019 to all NIH-supported research involving human subjects.

1. Medications Development for the Treatment of Alcohol Use Disorder - CT optional

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-AA-18-009\)](#)

Type: U01

Application Due Date: March 20, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for research that advances promising compounds through the drug development pipeline for the treatment of Alcohol Use Disorder (AUD). NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. The aim of this FOA is to move candidate compounds through Investigational New Drug (IND) requirements, Phase 1 human safety, tolerability, and dosing studies, and Phase 2 human laboratory and proof-of-concept trials. Within these phases of drug development, each proposed project should have a defined entry and exit point. Finally, this FOA will not support animal studies to prove efficacy of the candidate compound unless required by the Food and Drug Administration or peer review. Applicants are strongly encouraged to contact the NIAAA Division of Medications Development Staff prior to submitting to this FOA

Budget: NIH intends to fund an estimate of 4 awards, corresponding to a total of \$3.0 M, for fiscal year 2018. Budgets must not exceed \$1.0 M direct costs per year for IND enabling studies and \$500,000 direct cost for Phase 2 human laboratory and proof-of-concept clinical trials may be requested. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-569\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages R01 grant applications to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is 5 years.

3. Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-583\)](#)

Type: X01

Application Due Date: March 22, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing are available for tumor or affected tissue when justified. These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

Budget: Not applicable; there are no funds associated with a resource access award. The scope of the proposed project should determine the project period. The maximum project period is 1 year.

4. The Human BioMolecular Atlas Program (HuBMAP) Integration, Visualization and Engagement (HIVE) Initiative (OT2 Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-RM-18-001\)](#)

Type: OT2

Application Due Date: April 16, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to establish the HuBMAP Integration, Visualization & Engagement (HIVE) Collaboratory that will: 1) manage the data generated by the HuBMAP Consortium, 2) coordinate internal and external Consortium activities, 3) develop novel tools for visualizing, searching and modelling data and 4) build an atlas of tissue maps. The HIVE will be composed of four Components all of which are expected to work closely together to act as the unified backbone for the HuBMAP. The HIVE is expected to work closely with the other funded projects as part of the HuBMAP Consortium to catalyze development of a framework for mapping the human body with high spatial resolution. An application may propose only one Component. However, a coordinated set of separate applications, each describing a separate Component but with a common vision, can be proposed.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. OT2 applications will be required to provide a well-justified budget that is appropriate for the scope of the proposed work. Costs should be based upon how much money is required to produce the deliverables. The scope of the proposed project should determine the project period. The maximum proposed project period is 4 years, but awards may be terminated earlier or extended based on programmatic requirements.

5. Development of Cell and Tissue Platforms to Detect Adverse Biological Consequences of Somatic Cell Gene Editing (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-RM-18-015\)](#)

Type: U01

Application Due Date: April 3, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications that propose to develop and validate tissue- and cell-based platforms for assessing potential adverse biological consequences of somatic cell genome editing.

Budget: The NIH Common Fund (Office of Strategic Coordination) intends to commit up to \$5.0M per year in FY 2018 - 2022 to fund up to eight awards, contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets should not exceed \$390,000 direct costs per year in FY 2018-2022 and need to reflect the actual needs of the proposed project. The maximum project period is five years (FY2018-2022).

6. Innovative Technologies to Deliver Genome Editing Machinery to Disease-relevant Cells and Tissues (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-RM-18-016\)](#)

Type: UG3/UH3

Application Due Date: April 3, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this FOA is to support the development and evaluation of innovative approaches to deliver genome editing machinery into somatic cells, with the ultimate goal of accelerating the development of genome editing therapeutics to treat human disease.

Budget: The NIH Common Fund (Office of Strategic Coordination) intends to commit \$7.5M in FY 2018-2020 and \$12.0M in FY2021-2022 to fund up to ten awards, contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets should not exceed \$500,000 direct costs per year for the UG3 Phase (FY 2018-2020) and \$1M for the UH3 Phase (FY 2021-2022). The maximum project period is 5 years (FY 2018-FY2022).

7. Expanding the Human Genome Editing Repertoire (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-RM-18-017\)](#)

Type: U01

Application Due Date: April 3, 2018 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications proposing research on the development of novel and optimized alternatives to existing in vivo genome editing complexes.

Budget: The NIH Common Fund (Office of Strategic Coordination) intends to commit \$1.0M in FY 2018 to fund up to three awards, contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets should not exceed \$250,000 direct cost per year in FY 2018 - FY 2022 and need to reflect the actual needs of the proposed project. The maximum project period is 5 years (FY 2018 - 2022).

8. Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-591\)](#)

Type:

Application Due Date: Due dates may vary by awarding IC. See the awarding IC web site for any applicable Application Due Dates. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements. A list of those web sites is available at https://grants.nih.gov/grants/guide/admin_supp/index.htm.

Budget: Application budgets are limited to no more than the amount of the current parent award, and must reflect the actual needs of the proposed project. The funding mechanism being used to support this program, administrative supplements, can be used to cover cost increases that are associated with achieving certain new research objectives, as long as the research objectives are within the original scope of the peer reviewed and approved project, or the cost increases are for unanticipated expenses within the original scope of the project. Any cost increases need to result from making modifications to the project that would increase or preserve the overall impact of the project consistent with its originally approved objectives and purposes. The project and budget periods must be within the currently approved project period for the existing parent award.

9. Pragmatic Trials for Dementia Care in Long-term Services and Support (LTSS) Settings (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink:

Type: R61/R33

Application Due Date: March 27, 2018; February 20, 2019; and February 2020. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA invites applications for pragmatic trials for dementia care in Long-term Services and Support (LTSS) settings which will: (1) be designed to address practical comparative questions faced by Alzheimer's disease (AD) and AD-related dementia (ADRD) patients, clinicians and caregivers (both paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings. These trials are intended to produce results that can be directly adopted by healthcare providers, patients or caregivers for rapid translation. Successful applications will: (1) improve quality of care of persons with dementia; (2) improve quality of life for persons with dementia and their informal caregivers; (3) deliver more patient-focused, cost-effective care in LTSS; and/or (4) reduce disparities in LTSS care. This FOA will support pilot research to test the feasibility of implementing and integrating LTSS interventions (R61 phase) that, if successful, can transition to an R33 phase for implementation of large pragmatic trials. The transition from the R61 to the R33 phase of the award will be administratively reviewed and determined by successful completion of the Go/No-Go Criteria that are specified for the R61 phase.

Budget: For the R61 planning phase, the combined budget for direct costs for up to two years may not exceed \$500,000. For the R33 phase, budgets are expected to go over \$500,000. Applicants requesting \$500,000 or more in direct costs during the R33 phase in any year (excluding consortium F&A) must contact a Scientific/Research Contact at least 6 weeks before submitting the application. The project period is limited to 5 years, which includes up to 2 years of the R61 phase, followed by up to 4 years of the R33 phase.

10. Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-601\)](#)
[\(PA-18-602\)](#)
[\(PA-18-603\)](#)

Type: R03
R21
R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this FOA is two-fold: (1) to advance identification of male-female differences in drug and alcohol research outcomes, to uncover the mechanisms of those differences, and to conduct translational research on those differences, and (2) to advance research specific to women or highly relevant to women. Both preclinical and clinical studies are sought across all areas of drug and alcohol research.

Budget: R03- Application budgets are limited to \$50,000 in direct costs per year. The maximum period is 2 years. R21- The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum period is 2 years. R01- Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum period is 5 years.

11. Pilot and Feasibility Studies of HIV and Animal Models for HIV Infection within the Mission of NIDDK (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-615\)](#)

Type: R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications for innovative basic and translational research projects examining HIV infection, persistence, and comorbidities as they relate to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) in [NOT-OD-15-137: NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding](#).

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000, exclusive of any consortium F&A costs per year. No more than \$200,000 may be requested in any single year. The total project period may not exceed 2 years.

12. Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-619\)](#)
[\(PA-18-620\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this FOA is encourage applications that seek to examine processes of recovery and relapse in the treatment of Alcohol Use Disorders. Applications high in innovation and significance are highly encouraged that address the following potential topics: 1) defining recovery; 2) Examining new and innovative methods to examine precipitants of relapse; 3) Understanding mechanisms of mutual help and recovery; 4) Evaluating recovery systems of care; and 5) Examining processes of extended treatment for AUD.

Budget: R01- Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years. R21-The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is two years

13. Disease Mechanisms of Prenatal and Pediatric Hydrocephalus (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-622\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven research of prenatal and pediatric hydrocephalus. This FOA intends to support hydrocephalus research projects that examine the developmental etiology (intrinsic factors including genetics) and acquired etiology (extrinsic factors including hemorrhage and infection) of prenatal and/or pediatric hydrocephalus. Studies should focus on understanding the molecular, cellular and developmental mechanisms involved in the pathogenesis of prenatal and/or pediatric hydrocephalus.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

14. Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-623\)](#)

Type: R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to encourage research grant applications that propose to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. The primary objective of this FOA is to remove barriers to hydrocephalus research that are due to scarcity of tools to investigate both the disease mechanisms and alternative therapies (non-shunt) in a rigorous manner. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

15. NIDA Small Research Grant Program (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-626\)](#)

Type: R03

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIDA Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of NIDA.

Budget: Application budgets are limited to \$50,000 in direct costs per year. The total project period may not exceed two years.

16. Research on Current Topics in Alzheimer's Disease and Its Related Dementias (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-596\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to invite applications proposing research on current topics in Alzheimer's disease and its related dementias. Further information on the high priority topics of interest will be announced through a series of notices published in late January and early February of 2018.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

17. Vet-LIRN Network Capacity-Building Projects

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-604\)](#)

Type:

Application Due Date: April 2, 2018 July 2, 2018 February 1, 2019, May 1, 2019, September 2, 2019 February 3, 2020, May 1, 2020, September 1, 2020 February 1, 2021, May 3, 2021, September 1, 2021 February 1, 2022, May 2, 2022, September 1, 2022 February 1, 2023, May 1, 2023, September 1, 2023 by 11:59 PM *Eastern Time*.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support enhanced human and animal food safety by strengthening the capacity, collaboration, and integration of food-safety laboratories and networks, thereby facilitating an effective and coordinated response to future human and animal food safety issues. The current FOA solicits applications from FDA's

Veterinary Laboratory Investigation and Response Network laboratories for research related to emerging public food safety issues identified by the Vet-LIRN network office (VPO), for equipment and personnel necessary to expand laboratory capability and capacity, and for other related activities. This cooperative agreement program is intended to build domestic laboratory capacity as put forth in the Food Safety Modernization Act (FSMA), by developing the Vet-LIRN laboratory Network capabilities and capacity to investigate potential animal foodborne illness outbreaks. In areas for potential research and related activities identified by the VPO program office, the Cooperative agreements will support research and other related activities that will:

1. Support short term surveillance efforts; 2. Support training, quality assurance processes, proficiency evaluations, data sharing to support national capacity/capability development;
2. Support the identification and adoption of emerging technologies and the harmonization of analytical methods used by new equipment platforms;
3. Support method development and validation projects; Matrix expansion projects may be needed with short turn-around times;
4. Support purchase of equipment needed for testing or developing tests for food/feed related samples.
5. Support emergency surge capacity testing during large-scale animal food/feed emergency events requiring testing of implicated diagnostic or animal food samples
6. Support travel to Network meetings to provide information to FDA on network projects.

Budget: The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support and, depending on the project, include future recommended support for four (4) additional year(s) contingent upon annual appropriations, availability of funding and satisfactory awardee performance. Most projects are expected to be short term and funded for one (1) year. It is anticipated that up to twenty awards will be made, not to exceed \$225,000 in total costs (direct plus indirect), per award. Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect):

YR 01: \$225,000
 YR 02: \$225,000
 YR 03: \$225,000
 YR 04: \$225,000
 YR 05: \$225,000.

The funds requested are expected to vary based on the complexity of the project and the number of collaborators involved. Most short-term priority Vet-LIRN Program Office projects are expected to fall in the \$20,000-50,000 direct cost range.

18. Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-605\)](#)
[\(PAR-18-606\)](#)

Type: R01
 R21

Application Due Date: April 11, 2018; October 10, 2018; April 11, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as "chemobrain." A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

Budget: R01- Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. R21- The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

19. Traceback Testing: Increasing Identification and Genetic Counseling of Mutation Carriers through Family-based Outreach (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-616\)](#)

Type: U01

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of the Funding Opportunity Announcement (FOA) is to support pilot research projects using a "Traceback" approach to genetic testing women with a personal or family history of ovarian cancer and reaching out to family members to identify unaffected individuals at increased risk for cancer in different clinical contexts and communities, including racially/ethnically diverse populations.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 4 years.

20. Mechanistic investigations of psychosocial stress effects on opioid use patterns (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAS-18-624\)](#)
[\(PAS-18-625\)](#)

Type: R01
 R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) invites innovative research to characterize the consequences of psychosocial stress on affective/cognitive functioning and/or pain processing as it relates to opioid use disorder (OUD). This FOA encourages research that elucidates mechanisms of action and determinants of vulnerability and/or resilience by which psychosocial stress influence OUD trajectories. Research using basic or clinical approaches is appropriate.

Budget: R01: NIH intends to fund an estimate of 3-5 awards, corresponding to a total of \$2 million dollars, for fiscal year 2019. OBSSR intends to commit \$500,000 in FY 2019 to fund 1-2 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. R21: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. The maximum project period is 2 years..

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).